Klaus Kucher

975 total citations
19 papers, 669 citations indexed

About

Klaus Kucher is a scholar working on Cellular and Molecular Neuroscience, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Klaus Kucher has authored 19 papers receiving a total of 669 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Cellular and Molecular Neuroscience, 4 papers in Pulmonary and Respiratory Medicine and 4 papers in Genetics. Recurrent topics in Klaus Kucher's work include Blood properties and coagulation (4 papers), Venomous Animal Envenomation and Studies (4 papers) and Neuroscience and Neuropharmacology Research (3 papers). Klaus Kucher is often cited by papers focused on Blood properties and coagulation (4 papers), Venomous Animal Envenomation and Studies (4 papers) and Neuroscience and Neuropharmacology Research (3 papers). Klaus Kucher collaborates with scholars based in Switzerland, Germany and United States. Klaus Kucher's co-authors include Beate Kiese, Daniela Eser, Thomas C. Baghai, Rainer Rupprecht, Cornelius Schüle, Frédérique Chaperon, Kevin H. McAllister, C. Gentsch, Hans O. Kalkman and Christophe Drieu La Rochelle and has published in prestigious journals such as Science, Blood and Annals of the New York Academy of Sciences.

In The Last Decade

Klaus Kucher

19 papers receiving 656 citations

Peers

Countries citing papers authored by Klaus Kucher

Since Specialization

Citations

This map shows the geographic impact of Klaus Kucher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaus Kucher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaus Kucher more than expected).

Fields of papers citing papers by Klaus Kucher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaus Kucher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaus Kucher. The network helps show where Klaus Kucher may publish in the future.

Co-authorship network of co-authors of Klaus Kucher

This figure shows the co-authorship network connecting the top 25 collaborators of Klaus Kucher. A scholar is included among the top collaborators of Klaus Kucher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klaus Kucher. Klaus Kucher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Interim Analysis of Safety and Hematological Parameters of an Ongoing Long-Term Open-Label Extension Study of Investigational PI3Kδ Inhibitor Leniolisib for Patients with Activated PI3K Delta Syndrome (APDS) through December 2021 2022 ·Blood ·V. Koneti Rao, Sharon Webster, Anna Šedivá, Alessandro Plebani, Catharina Schuetz, Anna Shcherbina, Virgil A. S. H. Dalm, Antonino Trizzino, (unknown), (unknown), (unknown), (unknown), Julia Körholz, Vassilios Lougaris, Yulia Rodina, Klaus Kucher, (unknown), (unknown), (unknown)	5
2	Efficacy and safety of single- and repeated-selurampanel dosing for 2 weeks in patients with chronic subjective tinnitus: Results of a randomized, double-blind, placebo-controlled, cross-over, proof-of-concept phase IIa study 2021 ·Progress in brain research ·Klaus Kucher, Donald R. Johns, Frank Wagner, (unknown), (unknown), Oleksandr Sverdlov, C. Pfister, Berthold Langguth	2
3	Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti-C5 monoclonal antibody tesidolumab 2020 ·American Journal of Transplantation ·Stanley C. Jordan, Klaus Kucher, Morten Bagger, Hans Hockey, Kristina Wagner, Noriko Ammerman, Ashley Vo	21
4	First-in-Man Intrathecal Application of Neurite Growth-Promoting Anti-Nogo-A Antibodies in Acute Spinal Cord Injury 2018 ·Neurorehabilitation and neural repair ·Klaus Kucher, Donald R. Johns, Doris Maier, Rainer Abel, Andreas Badke, (unknown), Roland Thietje, Steven Casha, Renate Ch. Meindl, Baltazar Gomez‐Mancilla, C. Pfister, Rüdiger Rupp, Norbert Weidner, Anis K. Mir, Martin E. Schwab, Armin Curt	124
5	CYP3A but not P‐gp plays a relevant role in thein vivointestinal and hepatic clearance of the delta‐specific phosphoinositide‐3 kinase inhibitor leniolisib 2018 ·Biopharmaceutics & Drug Disposition ·Stefan Buck, Klaus Kucher, Hisanori Hara, (unknown), Ralph Woessner	7
6	Safety and Efficacy of Long Term Suppression of PI3Kinase Pathway By Small Molecule PI3K-Delta Inhibitor, Leniolisib in Apds (Activated PI3Kδ Syndrome) 2018 ·Blood ·V. Koneti Rao, Sharon Webster, Virgil A. S. H. Dalm, Anna Šedivá, P. Martin van Hagen, (unknown), Les Folio, Maciej Cabanski, Marie‐Anne Valentin, Stefan Buck, Christoph Kalis, (unknown), Christoph Burkhart, Klaus Kucher, (unknown), Gülbû Uzel	6
7	O1‐10‐06: Results From a First‐in‐Human Study with the Bace Inhibitor CNP520 2016 ·Alzheimer s & Dementia ·Mike Ufer, Marie‐Laure Rouzade‐Dominguez, Gunilla Huledal, Nicole Pezous, Alexandre Avraméas, Olivier David, Sandrine Kretz, Klaus Kucher, Ulf Neumann, Jang‐Ho Cha, Ana Graf, Cristina Lopez‐Lopez	9
8	Dose‐dependent suppression of human photoparoxysmal response with the competitive AMPA/kainate receptor antagonist BGG492: Clear PK/PD relationship 2015 ·Epilepsia ·Dorothée Kasteleijn‐Nolst Trenité, Christian Brandt, (unknown), Felix Rosenow, Bernd Schmidt, Bernhard J. Steinhoff, Anne Gardin, Georges Imbert, Donald R. Johns, Alexandros Sagkriotis, Klaus Kucher	23
9	AQW051, a novel, potent and selectiveα7 nicotinicAChreceptor partial agonist: pharmacological characterization and phaseIevaluation 2014 ·British Journal of Pharmacology ·Dominik Feuerbach, Nicole Pezous, H. Weiss, Kasra Shakeri‐Nejad, Kurt Lingenhoehl, Daniël Hoyer, Konstanze Hurth, Graeme Bilbe, Christopher R. Pryce, Kevin H. McAllister, Frédérique Chaperon, Klaus Kucher, Donald R. Johns, Thomas Blaettler, Cristina López López	27
10	Translocator Protein (18 kD) as Target for Anxiolytics Without Benzodiazepine-Like Side Effects 2009 ·Science ·Rainer Rupprecht, Gerhard Rammes, Daniela Eser, Thomas C. Baghai, Cornelius Schüle, Caroline Nothdurfter, Thomas Troxler, C. Gentsch, Hans O. Kalkman, Frédérique Chaperon, (unknown), Kevin H. McAllister, Valérie Bertaina‐Anglade, Christophe Drieu La Rochelle, Dietrich Tuerck, (unknown), Beate Kiese, Michaël Schumacher, Rainer Landgraf, (unknown), Klaus Kucher	272
11	Cannabinoid Receptor Agonist 13, a Novel Cannabinoid Agonist: First in Human Pharmacokinetics and Safety 2009 ·Drug Metabolism and Disposition ·Anne Gardin, Klaus Kucher, Beate Kiese, Silke Appel‐Dingemanse	26
12	Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study 2007 ·Psychopharmacology ·Daniela Eser, Cornelius Schüle, Thomas C. Baghai, (unknown), Axel Krebs‐Brown, (unknown), Stephan de la Motte, Rolf R. Engel, Klaus Kucher, Rainer Rupprecht	38
13	Plasminogen Activation Without Changes in tPA and PAI-1 in Response to Subcutaneous Administration of Ancrod 2001 ·Thrombosis Research ·Carl-Erik Dempfle, Sonja Alesci, Klaus Kucher, (unknown), Klaus Rübsamen, Martin Borggrefe	13
14	Fibrin Formation and Proteolysis during Ancrod Treatment 2001 ·Annals of the New York Academy of Sciences ·Carl-Erik Dempfle, (unknown), Sonja Alesci, Klaus Kucher, (unknown), Klaus Rübsamen, D. L. Heene	11
15	Analysis of fibrin formation and proteolysis during intravenous administration of ancrod 2000 ·Blood ·Carl‐Erik Dempfle, (unknown), Klaus Kucher, (unknown), Klaus Rübsamen, D. L. Heene	1
16	Analysis of fibrin formation and proteolysis during intravenous administration of ancrod 2000 ·Blood ·Carl‐Erik Dempfle, (unknown), Klaus Kucher, (unknown), Klaus Rübsamen, D. L. Heene	40
17	Chronopharmacology of intravenous and oral modified release verapamil 1999 ·British Journal of Clinical Pharmacology ·Karin Dilger, Klaus Eckhardt, Ute Hofmann, Klaus Kucher, Gerd Mikus, Michel Eichelbaum	25
18	Role of cytochrome P4502D6 in the metabolism of brofaromine 1993 ·European Journal of Clinical Pharmacology ·(unknown), Klaus Kucher, (unknown), (unknown), (unknown), K. H. Antonin, P. R. Bieck, C H Gleiter	15
19	INVESTIGATION OF DOSE PROPORTIONALITY AND ABSOLUTE BIOAVAILABILITY OF BROFAROMINE IN HEALTHY VOLUNTEERS 1992 ·Clinical Neuropharmacology ·K. H. Antonin, Klaus Kucher, (unknown), P. R. Bieck, Erika Schmidt	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact